In a warning letter, USFDA summarised significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals, pointing out the company's failure to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/ZDUvbIL
0 Comments